Adial Pharmaceuticals, Inc (ADIL)
Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for addiction and other neurological disorders. The company’s main product candidate is aimed at treating alcohol use disorder by targeting specific neurological pathways. Adial aims to provide effective treatments for addiction-related conditions through innovative pharmacological approaches.
Company News
The substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.
Adial Pharmaceuticals has progressed to the second cohort in the pharmacokinetics study of its lead investigational drug AD04 for Alcohol Use Disorder. The study is expected to be completed in the fourth quarter of 2024, and the results will provide insights for the upcoming Phase 3 clinical trial.
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Here's 3 top tips for investing in penny stocks in the long term The post Finding Long Term Penny Stocks Investments? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.